UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-Q

 

(Mark One)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2012 or

 

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________.

 

Commission file number 1-08789

 

 

American Shared Hospital Services

(Exact name of registrant as specified in its charter)

 

California		94-2918118
(State or other jurisdiction of		(IRS Employer
Incorporation or organization)		Identification No.)

 

Four Embarcadero Center, Suite 3700, San Francisco, California	94111
(Address of Principal Executive Offices)	(Zip Code)

 

Registrant’s telephone number, including area code: (415) 788-5300

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ¨     Accelerated Filer ¨     Non-Accelerated Filer ¨      Smaller reporting company x

 

As of May 1, 2012, there are outstanding 4,611,560 shares of the Registrant’s common stock.

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

		(unaudited)
		March 31, 2012				December 31, 2011
ASSETS
Current assets:
Cash and cash equivalents		$	1,788,000			$	2,580,000
Restricted cash			50,000				50,000
Certificate of deposit			9,000,000				9,000,000
Accounts receivable, net of allowance for doubtful accounts of $100,000 in 2012 and $100,000 in 2011			4,428,000				4,604,000
Other receivables			123,000				158,000
Prepaid expenses and other current assets			1,368,000				733,000
Current deferred tax assets			490,000				490,000
Total current assets			17,247,000				17,615,000
Property and equipment:
Medical equipment and facilities			80,647,000				80,647,000
Office equipment			692,000				692,000
Deposits and construction in progress			10,671,000				7,264,000
			92,010,000				88,603,000
Accumulated depreciation and amortization			(36,889,000	)			(35,336,000	)
Net property and equipment			55,121,000				53,267,000
Investment in preferred stock			2,656,000				2,656,000
Other assets			1,045,000				997,000
Total assets		$	76,069,000			$	74,535,000

  

		(unaudited)
		March 31, 2012				December 31, 2011
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	283,000			$	278,000
Employee compensation and benefits			152,000				255,000
Customer deposits/deferred revenue			485,000				497,000
Other accrued liabilities			1,459,000				1,298,000
Current portion of long-term debt			3,637,000				3,940,000
Current portion of obligations under capital leases			3,708,000				3,676,000
Total current liabilities			9,724,000				9,944,000
Long-term debt, less current portion			14,188,000				11,428,000
Long-term capital leases, less current portion			16,107,000				16,707,000
Advances on line of credit			7,500,000				7,850,000
Deferred income taxes			3,435,000				3,435,000
Shareholders' equity:
Common stock (4,612,000 shares at March 31, 2012
and 4,611,000 shares at December 31, 2011)			8,606,000				8,606,000
Additional paid-in capital			4,860,000				4,828,000
Retained earnings			6,777,000				6,768,000
Total equity-American Shared Hospital Services			20,243,000				20,202,000
Non-controlling interest in subsidiary			4,872,000				4,969,000
Total shareholders' equity			25,115,000				25,171,000
Total liabilities and shareholders' equity		$	76,069,000			$	74,535,000

 

See accompanying notes

 

 

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

		Three Months ended March 31,
		2012				2011
Medical services revenue		$	4,403,000			$	4,367,000
Costs of revenue:
Maintenance and supplies			390,000				344,000
Depreciation and amortization			1,545,000				1,427,000
Other direct operating costs			631,000				672,000
			2,566,000				2,443,000
Gross Margin			1,837,000				1,924,000
Selling and administrative expense			1,024,000				1,122,000
Interest expense			574,000				576,000
Operating income			239,000				226,000
Interest and other income			1,000				16,000
Income before income taxes			240,000				242,000
Income tax expense			11,000				23,000
Net income			229,000				219,000
Less: Net income attributable to non-controlling interest			(220,000	)			(198,000	)
Net income attributable to American Shared Hospital Services		$	9,000			$	21,000
Net income per share:
Earnings per common share - basic		$	-			$	-
Earnings per common share - diluted		$	-			$	-

 

See accompanying notes

 

 

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

 

		PERIODS ENDED DECEMBER 31, 2010 AND 2011 AND MARCH 31, 2012
										Additional												Non-controlling
		Common				Common				Paid-in				Retained				Sub-Total				Interests in
		Shares				Stock				Capital				Earnings				ASHS				Subsidiaries				Total
Balances at January 1, 2010			4,595,000			$	8,606,000			$	4,593,000			$	6,205,000			$	19,404,000			$	3,351,000			$	22,755,000
Stock based compensation expense			2,000				-				110,000				-				110,000				-				110,000
Cash distributions to non-controlling interests			-				-				-				-				-				(627,000	)			(627,000	)
Net income			-				-				-				57,000				57,000				749,000				806,000
Balances at December 31, 2010			4,597,000				8,606,000				4,703,000				6,262,000				19,571,000				3,473,000				23,044,000
Stock based compensation expense			14,000				-				125,000				-				125,000				-				125,000
Investment in subsidiaries by non-controlling interests			-				-				-				-				-				1,509,000				1,509,000
Cash distributions to non-controlling interests			-				-				-				-				-				(996,000	)			(996,000	)
Net income			-				-				-				506,000				506,000				983,000				1,489,000
Balances at December 31, 2011			4,611,000				8,606,000				4,828,000				6,768,000				20,202,000				4,969,000				25,171,000
Stock based compensation expense			1,000				-				32,000				-				32,000				-				32,000
Investment in subsidiaries by non-controlling interests			-				-				-				-				-				55,000				55,000
Cash distributions to non-controlling interests			-				-				-				-				-				(372,000	)			(372,000	)
Net income			-				-				-				9,000				9,000				220,000				229,000
Balances at March 31, 2012 (unaudited)			4,612,000			$	8,606,000			$	4,860,000			$	6,777,000			$	20,243,000			$	4,872,000			$	25,115,000

 

See accompanying notes

 

 

AMERICAN SHARED HOSPITAL SERVICES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

		Three Months ended March 31,
		2012				2011
Operating activities:
Net income		$	229,000			$	219,000
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization			1,548,000				1,453,000
Stock based compensation expense			32,000				38,000
Changes in operating assets and liabilities:
Receivables			211,000				(544,000	)
Prepaid expenses and other assets			(678,000	)			(168,000	)
Customer deposits/deferred revenue			(12,000	)			1,922,000
Accounts payable and accrued liabilities			63,000				477,000
Net cash from operating activities			1,393,000				3,397,000
Investing activities:
Payment for purchase of property and equipment			(3,143,000	)			(1,335,000	)
Investment in subsidiaries by non-controlling interests			55,000				397,000
Net cash from investing activities			(3,088,000	)			(938,000	)
Financing activities:
Principal payments on long-term debt			(1,068,000	)			(844,000	)
Principal payments on capital leases			(832,000	)			(689,000	)
Long term debt financing on property and equipment			3,525,000				-
Advances on line of credit			250,000				-
Payments on line of credit			(600,000	)			(600,000	)
Distributions to non-controlling interests			(372,000	)			(380,000	)
Net cash from financing activities			903,000				(2,513,000	)
Net change in cash and cash equivalents			(792,000	)			(54,000	)
Cash and cash equivalents at beginning of period			2,580,000				1,438,000
Cash and cash equivalents at end of period		$	1,788,000			$	1,384,000
Supplemental cash flow disclosure:
Cash paid during the period for:
Interest		$	620,000			$	622,000
Income taxes		$	28,000			$	11,000
Schedule of non-cash investing and financing activities
Acquisition of equipment with capital lease financing		$	264,000			$	352,000

 

See accompanying notes

 

 

AMERICAN SHARED HOSPITAL SERVICES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1.

Basis of Presentation

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly American Shared Hospital Services’ consolidated financial position as of March 31, 2012 and the results of its operations for the three month period ended March 31, 2012 and 2011, which results are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2011 have been derived from audited financial statements.

 

These unaudited consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2011 included in the Company’s 10-K filed with the Securities and Exchange Commission.

 

These financial statements include the accounts of American Shared Hospital Services (the “Company”) and its wholly-owned subsidiaries: OR21, Inc. (“OR21”); MedLeader.com, Inc. (“MedLeader”); and American Shared Radiosurgery Services (“ASRS”); ASRS’ majority-owned subsidiary, GK Financing, LLC (“GKF”); GKF’s wholly-owned subsidiaries, GK Financing U.K., Limited (“GKUK”) and Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”); ASHS’ majority owned subsidiary, Long Beach Equipment, LLC (“LBE”), GKF’s majority owned subsidiaries, Albuquerque GK Equipment, LLC (“AGKE”), Jacksonville GK Equipment, LLC (“JGKE”) and EWRS, LLC (“EWRS”), and EWRS’ wholly owned subsidiary, EWRS Tibbi Cihazlar Ticaret Ltd Sti (“EWRS Turkey”).

 

The Company through its majority-owned subsidiary, GKF, provided Gamma Knife units to nineteen medical centers as of March 31, 2012 in the states of Arkansas, California, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Texas and Wisconsin, and in Turkey.

 

GKF also provides radiation therapy equipment to the radiation therapy department at the Gamma Knife site in Turkey. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in the United States.

 

The Company formed the subsidiaries GKUK, GKPeru, EWRS and EWRS Turkey for the purposes of expanding its business internationally into the United Kingdom, Peru and Turkey; LBE to provide proton beam therapy services in Long Beach, California; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida. AGKE and EWRS Turkey began operation in the second quarter 2011 and JGKE began operation in the fourth quarter 2011. GKPeru, GKUK and LBE are not expected to begin operations in 2012.

 

 

During 2011 and 2012, the Company’s partner in its Turkey operation, its partners in the Albuquerque Gamma Knife operation, and its partners in the Jacksonville Gamma Knife operations have made investments in EWRS, AGKE and JGKE, respectively. These investments are included in the line item “Non-controlling interests in subsidiaries” in the Company’s financial statements.

 

The Company has only one operating segment. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Note 2.

Per Share Amounts

 

Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. For the three months ended March 31, 2012 basic earnings per share was computed using 4,611,000 common shares and diluted earnings per share was computed using 4,638,000 common shares and equivalents. For the three months ended March 31, 2011 basic earnings per share was computed using 4,597,000 common shares and diluted earnings per share was computed using 4,617,000 common shares and equivalents.

 

The computation for 2012 excluded approximately 289,000 of the Company’s stock options because the strike price of the options was higher than the average market price during the quarter. The computation for 2011 excluded approximately 355,000 of the Company’s stock options because the strike price of the options was higher than the average market price during the quarter.

 

Note 3.

Stock-based Compensation

 

On June 2, 2010, the Company’s shareholders approved an amendment and restatement of the 2006 Stock Incentive Plan (the “2006 Plan”). Among other things, the amendment and restatement renamed the 2006 Plan to the Incentive Compensation Plan (the “Plan”) and increased the number of shares of the Company’s common stock reserved for issuance under the Plan by an additional 880,000 shares from 750,000 shares to 1,630,000 shares. The shares are reserved for issuance to officers of the Company, other key employees, non-employee directors, and advisors. The Plan serves as successor to the Company’s previous two stock-based employee compensation plans, the 1995 and 2001 Stock Option Plans. The shares reserved under those two plans, including the shares of common stock subject to currently outstanding options under the plans, were transferred to the Plan, and no further grants or share issuances will be made under the 1995 and 2001 Plans. Under the Plan, there have been 81,000 restricted stock units granted, consisting primarily of annual automatic grants and deferred compensation to non-employee directors, and there are 575,000 options granted, of which 503,000 options are vested as of March 31, 2012.

 

 

Compensation expense associated with the Company’s stock-based awards to employees is calculated using the Black-Scholes valuation model. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award, usually the vesting period. Accordingly, stock-based compensation cost before income tax effect in the amount of $32,000 is reflected in net income for the three month period ended March 31, 2012, compared to $38,000 in the same period in the prior year. There were no options issued and no options exercised during the three month period ended March 31, 2012. There were no excess income tax benefits to report.

 

Note 4.

Convertible Preferred Stock Investment

 

As of March 31, 2012 and December 31, 2011 the Company has a $2,656,000 investment in the convertible preferred stock (“Preferred Stock”) of Mevion Medical Systems, Inc. (“Mevion”), formerly Still River Systems, Inc., representing an approximate 1.0% interest in Mevion. The Company accounts for this investment under the cost method.

 

The Preferred Stock is convertible at any time at the option of the holder into shares of common stock of Mevion at a conversion price, subject to certain adjustments, but initially set at the original purchase price. The Preferred Stock has voting rights equivalent to the number of common stock shares into which it is convertible, and holders of the Preferred Stock, subject to certain exceptions, have a pro-rata right to participate in subsequent stock offerings. In the event of liquidation, dissolution, or winding up of Mevion, the Preferred Stock holders have preference to the holders of common stock, and any other class or series of stock that is junior to the Preferred Stock. The Company does not have the right to appoint a member of the Board of Directors of Mevion.

 

The Company carries its investment in Mevion at cost and reviews it for impairment on a quarterly basis, or as events or circumstances might indicate that the carrying value of the investment may not be recoverable. The Company evaluated this investment for impairment at December 31, 2011 and reviewed it at March 31, 2012 in light of both current market conditions and the ongoing needs of Mevion to raise cash to continue its development of the first compact, single room PBRT system. Based on its analysis, the Company estimates that there is currently an unrealized loss (impairment) of approximately $1.3 million.

 

In assessing whether the impairment is other than temporary, we evaluated the length of time and extent to which market value has been below cost, the financial condition and near term prospects of Mevion and our ability and intent to retain our investment for a period sufficient to allow for an anticipated recovery in the market value. Although the investment is not without certain risk, and the manufacture of the first unit has taken longer than originally anticipated, the Company believes that the current market value is a temporary situation brought on solely due to the continuing downturn of the economy, and is not a reflection on the progress or viability of Mevion or its PBRT design. During the first quarter of 2012, Mevion announced that it had completed and submitted its final application to the FDA for 510(k) clearance for its MEVION S250 system, and that it had received the CE Mark certification which enables Mevion to market, sell and install these systems through the European Union and any country that recognizes the CE Mark. Based on the continuing progress being made by Mevion toward the manufacture and installation of the first single room PBRT system, the Company believes that our investment in Mevion is not other than temporarily impaired, and the fair value will increase so that the carrying value will be recovered.

 

 

Note 5.

Line of Credit

 

The Company has a $9,000,000 renewable line of credit with the Bank of America (the “Bank”) that has been in place since June 2004 and has a maturity date of August 1, 2013. The line of credit is drawn on from time to time as needed for equipment purchases and working capital. Amounts drawn against the line of credit are at an interest rate per year equal to the Bank’s prime rate minus 0.5 percentage point, or alternately, at the Company’s discretion, the LIBOR rate plus 1.0 percentage point, and are secured by the Company’s cash invested with the Bank. The Company is in compliance with all debt covenants required. The weighted average interest rate during the first three months of 2012 was 1.39%. At March 31, 2012, $7,500,000 was borrowed against the line of credit, compared to $7,850,000 at December 31, 2011.

 

Note 6.

Fair Value of Financial Instruments

 

The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability.

 

The carrying value of financial instruments including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and other accrued liabilities approximated their fair value as of March 31, 2012 and December 31, 2011 because of the relatively short maturity of these instruments. The fair value of the Company’s investment in preferred stock is estimated to be $1,383,000 at both March 31, 2011 and December 31, 2011. The Company used the offering price in private placements of Mevion’s preferred stock during 2011 to estimate the fair value under Level 2 of the hierarchy. The fair value of the Company’s various debt obligations, discounted at currently available interest rates was approximately $37,730,000 and $35,743,000 at March 31, 2012 and December 31, 2011, respectively. The fair value of the Company’s debt was estimated using Level 3 inputs.

 

Note 7.

Repurchase of Common Stock

 

In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 shares of its own stock on the open market, which the Board reaffirmed in 2008. The Company did not repurchase any of its stock during 2011 or the first quarter of 2012. There are approximately 81,000 shares remaining under this repurchase authorization.

 

 

Item 8.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This quarterly report to the Securities and Exchange Commission may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21^st Century® program, and the risks of investing in a development-stage company, Mevion Medical Systems, Inc. (“Mevion”), without a proven product. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 and the definitive Proxy Statement for the Annual Meeting of Shareholders to be held on June 7, 2012.

 

The Company had nineteen Gamma Knife units in operation at both March 31, 2012 and March 31, 2011. Three of the Company’s customer contracts are through subsidiaries where GKF or its subsidiary is the majority owner and managing partner. Thirteen of the Company’s nineteen current Gamma Knife customers are under fee-per-use contracts, and six customers are under retail arrangements. The Company’s two contracts to provide radiation therapy and related equipment services to existing Gamma Knife customers are considered retail arrangements. Retail arrangements are further classified as either turn-key or revenue sharing. Revenue from fee per use contracts is recorded on a gross basis as determined by each hospital’s contracted rate. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and is responsible for paying all the operating costs of the equipment. Revenue is recorded on a gross basis and estimated based on historical experience of that hospital’s contracts with third party payors. For revenue sharing arrangements the Company receives a contracted percentage of the reimbursement received by the hospital. The gross amount the Company expects to receive is recorded as revenue and estimated based on historical experience.

 

Medical services revenue increased by $36,000 to $4,403,000 for the three month period ended March 31, 2012 from $4,367,000 for the three month period ended March 31, 2011. Revenue from the Company’s radiation therapy contracts increased for the three month period by $245,000, to $495,000 from $250,000 for the same period in the prior year. The increase was due to a new contract that began operation in the fourth quarter 2011, and increased volume at its existing radiation therapy site. The increase in revenue from radiation therapy was partially offset by a $209,000 decrease in Gamma Knife revenue to $3,908,000 from $4,117,000 for the same period in the prior year. The decrease in Gamma Knife revenue was primarily due to one Gamma Knife unit being out of service for approximately one month for a cobalt reload and the loss of one unit that was sold to the customer in the third quarter 2011. Both of these units had historically had higher than average per procedure rates. Even though the total procedures performed in the first quarter 2012 were higher than the same period in the prior year, total revenue can fluctuate depending on the procedure mix among customers.

 

 

The number of Gamma Knife procedures increased by 25 to 514 in the first quarter 2012 from 489 in the same quarter in the prior year, primarily due to the start of operations at two new Gamma Knife sites that were not in operation during the first quarter 2011. Increases from these new sites were partially offset by the loss of procedures from two sites where the contracts ended during the latter part of 2011. The increase was also partially offset by one site that was out of service for approximately one month during the first quarter 2012 for a cobalt reload, and several other sites that had generally lower volume compared to the same period in the prior year.

 

Total costs of revenue increased by $123,000 to $2,566,000 for the three month period ended March 31, 2012 from $2,443,000 for the three month period ended March 31, 2011. Maintenance and supplies increased by $46,000 for the three month period ended March 31, 2012 compared to the same period in the prior year, primarily due to higher maintenance contract expense because the warranty period ended for three Gamma Knife units. Depreciation and amortization increased by $118,000 for the three month period ended March 31, 2012 compared to the same period in the prior year primarily because depreciation started on four new sites that began operation since the first quarter 2011. This was partially offset by a reduction in depreciation for three sites where depreciation was stopped because the remaining value of the equipment had reached its salvage value. Other direct operating costs decreased by $41,000 for the three month period ended March 31, 2012 compared to the same period in the prior year primarily due to lower operating costs in connection with the Company’s retail sites and lower marketing costs.

 

Selling and administrative costs decreased by $98,000 to $1,024,000 for the three month period ended March 31, 2012 from $1,122,000 for the three month period ended March 31, 2011. This decrease was primarily due to lower payroll related costs and accounting fees, partially offset by higher legal fees.

 

Interest expense decreased by $2,000 to $574,000 for the three month period ended March 31, 2012 from $576,000 for the three month period ended March 31, 2011. Higher interest expense on financing from three new Gamma Knife units and one radiation therapy unit was offset by lower interest expense on debt relating to the more mature units. The mature units have lower interest expense because interest expense decreases as the outstanding principal balance of each loan is reduced.

 

Interest and other income decreased by $15,000 to $1,000 for the three month period ended March 31, 2012 from $16,000 for the three month period ended March 31, 2011 primarily from a reduction in interest income due to low interest rates available on invested cash.

 

The Company had income tax expense of $11,000 for the three month period ended March 31, 2012 compared to income tax expense of $23,000 for the three month period ended March 31, 2011. The reduction in income tax expense is primarily due to lower taxable income attributable to American Shared Hospital Services. This is partially offset by a higher estimated effective annual income tax rate for 2012 of 56%, based on income attributable to American Shared Hospital Services, compared to an estimated 52% income tax rate used in the first quarter 2011.

 

Net income attributable to non-controlling interest increased by $22,000 to $220,000 for the three month period ended March 31, 2012 from $198,000 for the three month period ended March 31, 2011. Net income attributable to non-controlling interests represents net income earned by the 19% non-controlling interest in GKF, and net income of the non-controlling interests in various subsidiaries controlled by GKF. The decrease or increase in net income attributable to non-controlling interests reflects the relative profitability of GKF.

 

The Company had net income of $9,000, or $0.00 per diluted share, for the three month period ended March 31, 2012 compared to net income of $21,000, or $0.00 per diluted share, in the same period in the prior year. The decrease in net income was primarily due to a decrease in gross margin from operations, and was partially offset by lower selling and administrative costs and reduced interest and other income.

 

Liquidity and Capital Resources

 

The Company had cash and cash equivalents of $1,788,000 at March 31, 2012 compared to $2,580,000 at December 31, 2011. The Company’s cash position decreased by $792,000 due to payments for the purchase of property and equipment of $3,143,000, principal payments on long term debt and capital leases of $1,900,000, net pay downs on the Company’s line of credit with a bank of $350,000 and distributions to non-controlling interests of $372,000. These decreases were offset by net cash from operating activities of $1,393,000, long term debt financing on the purchase of equipment of $3,525,000, and an investment by a non-controlling interest of $55,000.

 

As of March 31, 2012, the Company has a $9,000,000 principal investment in a certificate of deposit with a bank at an interest rate of 0.45% and a maturity date in August 2012.

 

The Company has a two year renewable $9,000,000 line of credit with a bank, available as needed for equipment purchases and working capital. Amounts drawn against the line of credit are secured by the Company’s cash invested with the bank. At March 31, 2012 there was $7,500,000 drawn against the line of credit.

 

The Company has scheduled interest and principal payments under its debt obligations of approximately $4,896,000 and scheduled capital lease payments of approximately $5,253,000 during the next 12 months. The Company believes that its cash flow from operations and cash resources are adequate to meet its scheduled debt and capital lease obligations during the next 12 months.

 

The Company as of March 31, 2012 had shareholders’ equity of $25,115,000, working capital of $7,523,000 and total assets of $76,069,000.

 

 

Commitments

 

The Company has a $2,656,000 preferred stock investment in Mevion Medical Systems, Inc., a development stage company, which is considered a long-term investment on the balance sheet and is recorded at cost. As of March 31, 2012, the Company also has $2,500,000 in non-refundable deposits toward the purchase of three MEVION S250 proton beam radiation therapy (PBRT) systems from Mevion. For the first two systems, the Company has a commitment to pay total deposits of $3,000,000 per system until FDA approval is received, at which time the remaining balance is committed. For the third system, the Company has a commitment to pay total deposits of $500,000 until FDA approval is received, at which time the remaining balance is committed. The Company has entered into an agreement with a radiation oncology physician group which has contributed $100,000 towards the deposits on the third system. The three PRBT systems have anticipated delivery dates beginning in mid-2013. The Mevion PBRT system is not commercially proven and there is no assurance FDA approval will be received.

 

The Company has made non-refundable deposits totaling $6,831,000 towards the purchase of a Perfexion unit scheduled to be completed in the second quarter 2012 at a new customer site in Turkey, a LGK Model 4 Gamma Knife unit to be installed at a site in Peru, a Perfexion unit scheduled to be installed at a new customer site in Florida, and two Perfexion units scheduled to be installed at sites yet to be determined.

 

Including the commitments for the three MEVION S250 systems, the four Perfexion units and the LGK Model 4 Gamma Knife unit, the Company has total remaining commitments to purchase equipment in the amount of approximately $46,000,000. It is the Company’s intent to finance the remaining purchase commitments as needed, and financing has been obtained for the units in Peru and Turkey. However due to the current economic and credit market conditions it has been more difficult to obtain financing for the Company’s projects. The Company expects that it will be able to obtain financing on the commitments for the remaining Perfexion units, but will not receive financing commitments from a lender for its PBRT systems until Mevion obtains FDA approval on the MEVION S250. There can be no assurance that financing will be available for the Company’s current or future projects, or at terms that are acceptable to the Company.

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

The Company does not hold or issue derivative instruments for trading purposes and is not a party to any instruments with leverage or prepayment features. The Company does not have affiliation with partnerships, trust or other entities whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements, and therefore has no exposure to the financing, liquidity, market or credit risks associated with such entities. At March 31, 2012 the Company had no significant long-term, market-sensitive investments.

 

 

Item 4.

Controls and Procedures

 

Under the supervision and with the participation of our management, including our chief executive officer and our chief financial officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934. These controls and procedures are designed to ensure that material information relating to the company and its subsidiaries is communicated to the chief executive officer and the chief financial officer. Based on that evaluation, our chief executive officer and our chief financial officer concluded that, as of March 31, 2012, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to the chief executive officer and the chief financial officer, and recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

There were no changes in our internal control over financial reporting during the three months ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1.

Legal Proceedings.

None.

 

Item 1A.

Risk Factors

There are no changes from those listed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

 

Item 3.

Defaults Upon Senior Securities.

None.

 

Item 4.

[Removed and Reserved.]

 

Item 5.

Other Information.

None.

 

Item 6.

Exhibits.

(a)          Exhibits

The following exhibits are filed herewith:

 

31.1

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

  

31.2

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

AMERICAN SHARED HOSPITAL SERVICES

Registrant

 

Date:	May 15, 2012	/s/ Ernest A. Bates, M.D.
		Ernest A. Bates, M.D.
		Chairman of the Board and Chief Executive Officer
Date:	May 15, 2012	/s/ Craig K. Tagawa
		Craig K. Tagawa
		Senior Vice President
		Chief Operating and Financial Officer